| Literature DB >> 35425239 |
Almaz Zaki1,2, Md Nafe Aziz1, Rakhshan Ahmad1, Irshad Ahamad1, M Shadab Ali3,4, Durdana Yasin1, Bushra Afzal1, Syed Mansoor Ali2, Anita Chopra3, Vijay Hadda4, Pooja Srivastava5, Raj Kumar5, Tasneem Fatma1.
Abstract
Driven by the need to biosynthesize alternate biomedical agents to prevent and treat infection, silver nanoparticles have surfaced as a promising avenue. Cyanobacteria-derived nanomaterial synthesis is of substantive interest as it offers an eco-friendly, cost-effective, sustainable, and biocompatible route for further development. In the present study optimal conditions for synthesis of silver nanoparticles (AgNPs) were 1 : 9 v/v [cell extract: AgNO3 (1 mM)], pH 7.4, and 30 °C reaction temperatures. Synthesis of nanoparticles was monitored by UV-vis spectrophotometry and the maximum absorbance was observed at a wavelength of 420 nm. SEM with EDX analysis confirmed 96.85% silver by weight which revealed the purity of AgNPs. TEM & XRD analysis exhibited a particle size of ∼12 nm with crystalline nature. FTIR analysis confirmed the presence of possible biomolecules involved in the synthesis and stabilization of AgNPs. Decapping of AgNPs followed by SDS-PAGE, LCMS and MALDI TOF analysis elucidates the proteinaceous nature of the capping and stabilizing agent. Cyanobacterial-derived capped AgNPs showed more cytotoxicicity towards a non-small cell lung cancer (A549) cell line, free radical scavenger and an antimicrobial than de-capped AgNPs. In addition they showed significant synergistic characteristics with antibiotics and fungicides. The test revealed that the capped AgNPs were biocompatible with good anti-inflammatory properties. The blend of antimicrobial and biocompatible properties, coupled with their intrinsic "green" and facile synthesis, made these biogenic nanoparticles particularly attractive for future applications in nanomedicine. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35425239 PMCID: PMC8979216 DOI: 10.1039/d1ra08396a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1(A) Change in the intensity of the synthesized nanoparticles; (B) UV-vis spectra of synthesized AgNPs recorded at the different time interval.
Fig. 2SEM with EDX of capped AgNPs (A) water washed, (B) ethanol washed and (C) acetone washed.
Fig. 3(A) Zeta potential; (B) DLS analysis of protein capped AgNPs, AgNPs.
Fig. 4(A) XRD spectrum of capped AgNPs; (B) SEM with EDX graph with elemental percentage table; (C and D) TEM micrograph with histogram.
Fig. 5(A) Supernatant without and with SDS during decapping of ethanol washed AgNPs, (B) UV-visible absorbance decapped and capped AgNPs (Pellet dissolve in ethanol); (C) SDS PAGE of cell extract (I), decapped AgNPs (II) [SDS treated-dAgNPs], calcinated AgNPs (III) and capped AgNPs (IV); (D) SEM micrograph; (E) SEM with EDX of (ethanol washed) decapped AgNPs; (F) SEM with EDX of calcinated (ethanol washed) AgNPs.
Fig. 6FTIR analysis of capped [(c) water, (b) acetone and (d) ethanol washed), decapped (ethanol washed- (a) SDS treated and (e) calcinated] AgNPs and (f) aqueous cell extract.
Antibacterial activity of water washed and ethanol washed AgNPs
| Amount of nanoparticles | Capped AgNPs | Capped AgNPs | ||
|---|---|---|---|---|
| Water washed | Ethanol washed | |||
|
|
|
|
| |
| 5 μg | 9 ± 0.5 mm | 11 ± 0.4 mm | 19 ± 0.9 mm | 12 ± 0.8 mm |
| 10 μg | 12 ± 0.6 mm | 17 ± 0.7 mm | 23 ± 1.5 mm | 20 ± 1.5 mm |
| 15 μg | 14 ± 0.9 mm | 19 ± 1.1 mm | 25 ± 1.2 mm | 23 ± 1.6 mm |
| 20 μg | 16 ± 1.2 mm | 21 ± 1.5 mm | 27 ± 1.4 mm | 25 ± 1.8 mm |
Antibacterial activity of capped and decapped (ethanol washed-SDS treated) AgNPs
| Amount of nanoparticles | Decapped AgNPs | Capped AgNPs | ||
|---|---|---|---|---|
|
|
|
|
| |
| 5 μg | 10 ± 0.6 mm | 9 ± 0.5 mm | 19 ± 0.9 mm | 12 ± 0.8 mm |
| 10 μg | 13 ± 0.4 mm | 11 ± 0.6 mm | 23 ± 1.5 mm | 20 ± 1.5 mm |
| 15 μg | 15 ± 0.7 mm | 14 ± 0.9 mm | 25 ± 1.2 mm | 23 ± 1.6 mm |
| 20 μg | 16 ± 0.8 mm | 17 ± 1.1 mm | 27 ± 1.4 mm | 25 ± 1.8 mm |
Minimum inhibitory concentration (MIC) against pathogenic bacteria alone and in combination with antibiotic (streptomycin) along with interaction index. Experimentswere performed in triplicates; mean ± SD are shown
| MIC (μg) | Interaction index | |||||
|---|---|---|---|---|---|---|
| Bacteria | AgNPs | Streptomycin (strep.) | FIC (μg) | FIC index | Interaction mode | |
| AgNPs + strep. | ||||||
|
| 15.625 | 5.85 | 3.90 | 0.73 | 0.374 ± 0.12 | Synergistic |
|
| 18.75 | 8.59 | 4.68 | 1.07 | 0.374 ± 0.08 | Synergistic |
|
| 18.75 | 8.59 | 4.68 | 0.53 | 0.311 ± 0.04 | Synergistic |
|
| 15.625 | 5.85 | 3.90 | 0.73 | 0.374 ± 0.11 | Synergistic |
Minimum inhibitory concentration (MIC) against pathogenic fungus alone and in combination with antifungal (fluconazol) along with interaction index. Experimentswere performed in triplicates; mean ± SD are shown
| MIC (μg) | Interaction index | |||||
|---|---|---|---|---|---|---|
| Fungi | AgNPs | Fluconazole | FIC (μg) | FIC index | Interaction mode | |
| AgNPs + fluconazole | ||||||
|
| 14.06 | 7.81 | 3.51 | 0.68 | 0.336 ± 0.06 | Synergistic |
|
| 14.06 | 5.4 | 3.51 | 0.34 | 0.312 ± 0.06 | Synergistic |
Antioxidants properties of (PM, ABTS, FRAP, DPPH and NOR assay) of capped AgNPs
| Antioxidant activity (IC50) | Aqueous cell extract (ACE) (μg mL−1) | Capped AgNPs (μg mL−1) | Ascorbic acid (AA) (μg mL−1) |
|---|---|---|---|
| PM | 154.78 ± 2.13 | 87.20 ± 1.53 | 5.87 ± 0.023 |
| ABTS | 169.84 ± 2.53 | 42.87 ± 0.18 | 12 ± 0.05 |
| FRAP (EC1) | 324.5 ± 4.53 | 203 ± 2.42 | 9.29 ± 0.058 |
| DPPH | 176.03 ± 3.67 | 52.04 ± 1.45 | 6.24 ± 0.72 |
| NOR | 170.57 ± 4.15 | 54.04 ± 1.23 | 6.77 ± 0.03 |
Fig. 7(A and B) Anti-denaturation activity of protein against capped AgNPs as anti-inflammatory agent.
Fig. 8Experimental observation of the cytotoxic property of Plectonema-derived AgNPs: (A) cytotoxic activity of capped AgNPs at IC50 concentration against lung cancer cell line (A549); (B) A549 control; (C) cytotoxic activity (IC50) of capped AgNPs against normal (peripheral mononuclear blood cells) PMBC cells; (D) cytotoxic activity of capped, decapped AgNPs against A549 lungs cancer cell line and normal PMBC cells at different concentration. Experiments were performed in triplicates; the error bar represents statistically significant differences (p-value < 0.05).
Fig. 9Apoptosis analysis against lung cancer cell line (A549) cells determined by APC Annexin V/FITC apoptosis detection assay exposed to AgNPs.